Lyra Therapeutics (LYRA) Non Operating Income (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Non Operating Income of $169000.0 in Q4 2025, down 33.98% on a QoQ basis from $256000.0 in Q3 2025, and down 61.15% YoY from $435000.0 in Q4 2024.
Lyra Therapeutics (LYRA) Non Operating Income (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Non Operating Income for 7 consecutive years, with $169000.0 the latest figure, recorded in Q4 2025.
- Non Operating Income for Q4 2025 came in at $169000.0, down 61.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.1 million (down 28.39% YoY), and the FY2025 annual result was $2.1 million, down 28.39% from the prior year.
- Non Operating Income for Q4 2025 stood at $169000.0, down from $256000.0 in the prior quarter.
- The five-year high for Non Operating Income was $1.4 million in Q2 2025, with the low at $14000.0 in Q1 2022.
- A 5-year average of $535400.0 and a median of $366500.0 in 2024 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income surged 7557.14% in 2023 and slumped 72.56% in 2025, its largest moves.
- Lyra Therapeutics' Non Operating Income stood at $21000.0 in 2021, then jumped by 4342.86% to $933000.0 in 2022, then soared by 43.41% to $1.3 million in 2023, then plunged by 67.49% to $435000.0 in 2024, then tumbled by 61.15% to $169000.0 in 2025.
- The last three Non Operating Income figures came in at $169000.0 (Q4 2025), $256000.0 (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 169,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 169,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 298,000.00 |
| Dec 31, 2024 | 435,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 897,000.00 |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 933,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 34,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 29,000.00 |